Andrew Caravello, DO
@andrewcaravello • 2,090 subscribers
EM/IM physician. Author of The Biological Reboot. Exploring immune instruction, aging, cancer, infection and practical well-being through systems biology.
Videos
$NWBO #DCVax #DCVaxForBraelyn 𝗦𝗮𝗺𝗲 𝘃𝗮𝗰𝗰𝗶𝗻𝗲. 𝗦𝗮𝗺𝗲 𝗯𝗼𝗼𝘀𝘁𝗲𝗿. 𝗦𝗮𝗺𝗲 𝗞𝗲𝘆𝘁𝗿𝘂𝗱𝗮. 𝗢𝗻𝗹𝘆 𝘁𝗵𝗲 𝗼𝗿𝗱𝗲𝗿 𝗰𝗵𝗮𝗻𝗴𝗲𝗱. Vaccine first: 555 days. #Keytruda first: 271 days. Once #glioblastoma comes back, patients live six to ten months. The Keytruda-first arm, at 8.9 months, landed right where this disease always lands. Vaccine first: 18.2 months. Nothing close has been reported in a randomized trial of recurrent glioblastoma. A 2021 Cochrane review of the trials at first recurrence found medians between 5.5 and 12.6 months. The few higher numbers anywhere come from single-arm or retrospective studies that choose their own patients. This one was randomized. The reason fits in three lines. Keytruda takes the brakes off the immune system's killers. The vaccine teaches them what to kill. Teach first, then release. 𝗧𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘁𝗵𝗮𝘁 𝗺𝗮𝗱𝗲 𝗶𝘁 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝘄𝗮𝘀 𝘁𝗮𝗸𝗲𝗻 𝗶𝗻 𝟮𝟬𝟬𝟮, 𝗯𝘆 𝘁𝘄𝗼 𝗺𝗲𝗻 𝗮𝗹𝗺𝗼𝘀𝘁 𝗻𝗼𝗯𝗼𝗱𝘆 𝘄𝗮𝘀 𝗹𝗶𝘀𝘁𝗲𝗻𝗶𝗻𝗴 𝘁𝗼. 𝗧𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 UCLA reported it for EANO 2026 (NCT04201873): 16 patients randomized to the vaccine first, 19 to Keytruda first, all with the more aggressive, IDH wild-type form. Hazard ratio 0.32. The two groups did not differ significantly in how much tumor surgery left behind, or in mutation load. The booster in both arms is poly-ICLC, sold as Hiltonol. 𝗛𝗼𝘄 𝗶𝘁 𝘄𝗼𝗿𝗸𝘀 Keytruda kills nothing. It takes the brakes off T cells, the immune system's killers. That only helps if the killers already know what to attack. Teaching them is the job of the dendritic cell. It works like a switch. On, in what immunologists call the type-1 state, it gives the order to kill. Off, it goes silent, and a tumor is very good at holding it off. The vaccine is made of the patient's own dendritic cells, grown outside the body where nothing has switched them off, then loaded with the patient's own tumor. It arrives with the switch already on. And it reads the whole tumor, not a target someone chose. In 2008 one dose of this kind of vaccine, loaded with a man's own tumor, found a virus hiding in it that nobody knew was there. The cells found it because they were not looking for anything. Vaccine first, and the cells teach, and then Keytruda releases an army that knows its target. The trial saw it: more T cells inside the tumor, carrying interferon and granzyme B, the enzyme a killer T cell uses to destroy its target. Keytruda first: chronic inflammation instead. 𝗣𝗿𝗼𝗼𝗳 𝗯𝘆 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 The FDA's plausible mechanism pathway, set out by Vinay Prasad and Commissioner Marty Makary in the New England Journal of Medicine, asks five questions. This treatment answers all five. 1. A specific broken link? The dendritic cell's switch, held off by the tumor. 2. A product aimed at it? The patient's own dendritic cells, switched on outside the body. 3. A well-known untreated course? Six to ten months, measured in hundreds of trials. 4. Proof the target was hit? T cells in the tumor carrying interferon and granzyme B. 5. A better clinical course? 555 days against 271. The FDA's guidance adds one more test: the improvement must not come from other treatments or from the disease's natural variability. This trial rules out both. Same treatments in both arms. Randomized, balanced, p below 0.0006. The only thing that changed was whether the instruction came first. That is proof by mechanism. 𝗪𝗵𝗼 𝗯𝘂𝗶𝗹𝘁 𝗶𝘁 The UCLA vaccine is ATL-DC, the academic version of DCVax-L. DCVax-L is Northwest Biotherapeutics', and it was invented by Alton Boynton and Marnix Bosch. Boynton filed on dendritic cells loaded with a patient's own tumor in 1995, three years before he co-founded the company. Bosch joined in 2000 and built the manufacturing. Linda Liau, now chair of neurosurgery at UCLA, led the phase 3. Boynton and Bosch are the named inventors on the patents Northwest holds, and the last two authors on the papers she leads. Between 2002 and 2005 they made three decisions, each against where the field was going: 1. 2002: use the whole tumor, not a chosen target. 2. 2003: add interferon gamma, so the cells come out switched on. 3. 2005: stop the cells halfway and inject them straight into tumors that cannot be removed. The second is what makes the other two safe. The third became DCVax-Direct, for tumors a surgeon cannot remove. Both products carry the whole tumor. DCVax-L loads it in the lab, from the tumor the surgeon took out. DCVax-Direct loads it inside the patient. Wherever there is a tumor, they load the tumor. 𝗪𝗵𝘆 𝗶𝘁 𝗶𝘀 𝘀𝗮𝗳𝗲 In DCVax-L's phase 3, patients were given their own brain tumors back, ground up and loaded onto their own cells. Seven of 331 patients had a serious side effect even possibly related to the vaccine. No autoimmune reactions. 𝗧𝗵𝗲 𝗱𝗿𝘂𝗴𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝘃𝗲𝗿 𝗳𝗮𝗶𝗹𝗲𝗱 In 2020 a drug from the same class as Keytruda was tested on its own in recurrent glioblastoma and lost. Six years later the same class sat inside the arm that doubled survival. The drug had not changed. This time the switch was on when it arrived. We may already own many of the treatments we need. We have been giving them with the switch off. 𝗦𝘁𝗶𝗹𝗹 𝘄𝗮𝗶𝘁𝗶𝗻𝗴 DCVax-L's phase 3: 13.0 percent alive at five years against 5.7. DCVax-L has not been turned down by the FDA. It has not been submitted. In the UK, a review meant to take 150 days passed 1,000 in September 2026. Boynton is still chief scientific officer. Bosch is still chief technical officer. 𝗕𝗿𝗮𝗲𝗹𝘆𝗻 Braelyn Hollensbe was sixteen when they found it. She had surgery, and it came back. Surgeons at more than one major center looked at what was left and said no. Linda Liau said yes, and took about ninety percent. Hers is the kind of glioblastoma standard chemotherapy works least well against. Then her family started flying from South Carolina to London for DCVax-L, the vaccine Boynton and Bosch invented and Northwest builds from a patient's own tumor, because it is not licensed where she lives. Three induction doses, then a fourth, fitted around the start of college. Then the Keytruda. In that order. On August 28 a scan went to Liau and the UCLA tumor board. What had been left behind at surgery was not there. On September 15 her mother wrote the sentence she had been waiting to write since Braelyn was sixteen: no evidence of disease. Everything above is an argument about order. For Braelyn it was a schedule. Flip the switch. Then amplify. The video walks through the whole mechanism.
Andrew Caravello, DO159,566 views • 19 days ago
$NWBO #DCVaxForBraelyn #GBM Siobhain, Margaret’s Trial deserves support. Your campaign could also put an urgent question to government: 𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 #𝗗𝗖𝗩𝗮𝘅-𝗟 𝘀𝘁𝗶𝗹𝗹 𝗮𝘄𝗮𝗶𝘁 𝗮𝗻 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻? Northwest Biotherapeutics has completed a phase III programme, published survival findings, documented a favourable safety record across thousands of doses, and developed a platform with a compelling rationale for combination treatment. The company and the people behind that work deserve to be part of this conversation. 𝗗𝗿. 𝗔𝗹𝘁𝗼𝗻 𝗕𝗼𝘆𝗻𝘁𝗼𝗻. 𝗗𝗿. 𝗠𝗮𝗿𝗻𝗶𝘅 𝗕𝗼𝘀𝗰𝗵. 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗼𝗿 𝗞𝗲𝘆𝗼𝘂𝗺𝗮𝗿𝘀 𝗔𝘀𝗵𝗸𝗮𝗻. Boynton co-founded Northwest. Bosch joined in 2000 and spearheaded development of its manufacturing and quality-control processes, alongside clinical protocols and regulatory submissions. Their work helped turn dendritic-cell biology into a personalised product that could be manufactured, transported and administered across an international clinical programme. That translation is an achievement in itself. Every patient supplies different cells and a different tumour. The treatment must still be prepared consistently enough to test and deliver. Here in Britain, Professor Keyoumars Ashkan, neurosurgeon at King’s College Hospital, served as the trial’s European Chief Investigator. He is a coauthor of the phase III publication, alongside UCLA’s Dr. Linda Liau, Boynton, Bosch and the international clinical team. 𝗕𝗿𝗶𝘁𝗶𝘀𝗵 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗵𝗲𝗹𝗽𝗲𝗱 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗲 𝘁𝗵𝗶𝘀 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲. The scientific argument begins with a basic requirement: the immune system needs effective instruction about what to attack. Dendritic cells present tumour antigens, provide activating signals and shape the responding T cells. Tumours can interfere with that process. DCVax-L makes preparation of those instructing cells part of treatment. The patient’s own dendritic cells are prepared outside the tumour environment and loaded with material from the patient’s own tumour. Whole-tumour material supplies a broad range of potential targets through the patient’s own presentation machinery. That matters in glioblastoma, where different cancer cells can carry different targets. 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝘀 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹 𝗱𝗼𝗶𝗻𝗴 𝘁𝗵𝗲 𝘁𝗲𝗮𝗰𝗵𝗶𝗻𝗴. The work discussed by Lisa Butterfield and Pawel Kalinski makes preparation even more consequential. Cells can pass routine checks while retaining signalling or metabolic defects. A mature appearance does not establish effective immune instruction. Starting-cell quality, culture conditions and maturation signals all shape function. IL-12p70 is an important part of type-1 instruction, but no single marker establishes the entire cell’s performance. This is why Bosch’s manufacturing work matters biologically. Preparing the cell creates an opportunity to assess and improve the instruction before treatment reaches the patient. 𝗧𝗵𝗲𝗻 𝘁𝗵𝗲 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. Pembrolizumab releases inhibition on T cells. Dendritic-cell vaccination can help generate the tumour-directed response that checkpoint treatment is intended to support. UCLA’s EANO 2026 report examined its related ATL-DC vaccine with poly-ICLC and pembrolizumab in recurrent glioblastoma. Among the analysed IDH-wildtype patients: 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗲𝗱 𝗯𝘆 𝗽𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯: 𝟱𝟱𝟱 𝗱𝗮𝘆𝘀 𝗺𝗲𝗱𝗶𝗮𝗻 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹. 𝗣𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯 𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝘂𝗿𝗴𝗲𝗿𝘆 𝗮𝗻𝗱 𝗮𝗹𝗼𝗻𝗴𝘀𝗶𝗱𝗲 𝘃𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗼𝗻: 𝟮𝟳𝟭 𝗱𝗮𝘆𝘀. The groups contained 16 and 19 patients. This small, amended trial also found greater T-cell infiltration and interferon/granzyme-B signals in the vaccine-first group. Earlier/concurrent treatment was associated with chronic inflammatory responses. Elevated interferon responses before treatment tracked with shorter survival. The distinction matters: timing, location and the state of the immune system can change what an immune signal accomplishes. 𝗘𝘀𝘁𝗮𝗯𝗹𝗶𝘀𝗵 𝘁𝗵𝗲 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲. 𝗧𝗵𝗲𝗻 𝗵𝗲𝗹𝗽 𝗶𝘁 𝘄𝗼𝗿𝗸. EANO 2026, abstract MO03.4.A: Trial: The vaccine course allowed only three doses, two weeks apart. Pembrolizumab continued; vaccination ended within weeks. A short course was followed by a survival difference measured months later. Immune memory, recruitment of the patient’s own dendritic cells, reciprocal signalling and recognition of additional tumour targets offer biological routes to a response that outlasts the injected cells. Their contribution requires measurement, but the possibility is central to the strategy. And 555 days is the median. Longer follow-up is needed to reveal the survival tail. 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗵𝗮𝘀 𝗮 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝗱 𝗳𝗶𝘃𝗲-𝘆𝗲𝗮𝗿 𝘁𝗮𝗶𝗹. Northwest’s phase III publication reported five-year survival of 13.0% versus 5.7% in newly diagnosed glioblastoma, compared with external controls. At recurrence, median survival was 13.2 months versus 7.8 months. Across 2,151 doses, investigators reported five serious adverse events considered at least possibly treatment-related, with no evidence of autoimmune reactions or cytokine storm. The recurrence finding adds another important insight: those vaccines were manufactured from the original tumour. Forty-six of the 64 crossover patients had no second surgery. The original tumour material remained the basis of treatment after recurrence. DCVax-L’s phase III schedule also continued beyond initial priming, with repeat doses through month 30. That provides a rationale for studying reinforcement of the response. Comparing cell counts across different products cannot establish comparative potency; what matters is the immune response those cells generate. 𝗡𝗼𝗿𝘁𝗵𝘄𝗲𝘀𝘁 𝗵𝗮𝘀 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲. In July 2026, Bosch presented updated analyses using individual patient data. Northwest reported that independent statisticians applied propensity-score matching and inverse-probability weighting. The survival advantage persisted across methods and comparator datasets. Matching yielded median advantages of 3.4–6.3 months. More detailed comparisons strengthened the reported signal. Full publication will allow independent scrutiny. The company’s broader development programme follows the same biological logic: Prepare effective dendritic cells. Present a broad range of tumour targets. Generate and, where appropriate, expand tumour-reactive cells. Help them enter the tumour. Address suppression and study checkpoint timing. Investigate how to reinforce and sustain the response. Northwest has licensed complementary technologies developed by Kalinski’s teams. DCVax-Direct explores acquiring tumour material inside the body. Its Flaskworks/Eden programme addresses the manufacturing capacity needed to deliver personalised cell treatment more widely. These programmes require their own validation. Their significance is the connected strategy: improving the instructor, supporting the responding cells and building the means to manufacture treatment at scale. 𝗧𝗵𝗲 𝗽𝗲𝗼𝗽𝗹𝗲 𝘄𝗵𝗼 𝗯𝘂𝗶𝗹𝘁 𝘁𝗵𝗶𝘀 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗯𝗲 𝗵𝗲𝗮𝗿𝗱. The UK application was submitted in December 2023. In July 2026, Northwest reported MHRA confirmation that it remained under review and had not been refused. Siobhain, please invite Northwest, Dr. Boynton, Dr. Bosch and Professor Ashkan to explain the evidence and the remaining steps directly to your campaign and parliamentary colleagues. Then ask government and the company for a clear account of what remains unresolved, who must resolve it, and when a decision can be reached. Press for a practical access plan alongside that work. DCVax-L’s survival findings, safety record and biological rationale make a compelling case for its potential role as a treatment foundation. The people who developed it and the clinicians who tested it can explain that case in detail. 𝗘𝘃𝗲𝗿𝘆 𝗿𝗲𝗺𝗮𝗶𝗻𝗶𝗻𝗴 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗻𝗲𝗲𝗱𝘀 𝗮𝗻 𝗼𝘄𝗻𝗲𝗿, 𝗮 𝗻𝗲𝘅𝘁 𝘀𝘁𝗲𝗽 𝗮𝗻𝗱 𝗮 𝘁𝗶𝗺𝗲𝘁𝗮𝗯𝗹𝗲. 𝗙𝗮𝗺𝗶𝗹𝗶𝗲𝘀 𝗮𝗿𝗲 𝗺𝗲𝗮𝘀𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝘁𝗶𝗺𝗲 𝗶𝗻 𝗯𝗶𝗿𝘁𝗵𝗱𝗮𝘆𝘀, 𝗴𝗿𝗮𝗱𝘂𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 𝗺𝗼𝗿𝗻𝗶𝗻𝗴 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿.
Andrew Caravello, DO61,089 views • 9 days ago
𝗧𝗵𝗲 $NWBO 𝗗𝗖𝗩𝗮𝘅-𝗟 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝘁𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗽𝗮𝘁𝗵𝘄𝗮𝘆. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. #DCVax-L is a vaccine made for each patient from their own dendritic cells, the immune cells that teach the rest of the immune system what to attack, loaded with their own tumor. It treats #glioblastoma, the deadliest brain cancer. An American company developed it, yet Americans have to go to Europe to get it. #DCVaxForBraelyn The FDA has spent the past year writing down how it wants to judge treatments like this one. The core evidence it asks for already exists. One question decides this: can the FDA evaluate DCVax-L for approval under the plausible mechanism framework, on the evidence already generated? Read against every document the agency has published on the framework, the answer is yes. 𝗧𝗵𝗲 𝗽𝗹𝗮𝗻 𝗶𝗻 𝘁𝗵𝗿𝗲𝗲 𝘀𝘁𝗲𝗽𝘀 1. File the biologics license application (BLA) and ask the FDA's biologics center (CBER) for review under the plausible mechanism framework. A BLA is not another trial. It is the dossier the FDA decides on, and the framework changes what counts as sufficient inside it. The framework itself needs no new statute and no special designation. A sponsor asks for it. 2. Ask for full approval on survival, with no new randomized trial. The completed phase 3 is the pivotal study. Mechanism, a related product, a related stage of the disease and independent natural history are the confirmatory evidence. A registry of every treated patient supplies the follow-up. 3. Open access alongside the filing. An expanded access treatment protocol does not have to wait for the BLA; it can begin 30 days after the FDA receives it. Filing the BLA satisfies Right to Try's application condition. 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗵𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗱𝗼𝘄𝗻 Nov 2025, NEJM, Prasad and Makary: the plausible mechanism framework. Five questions. Built for cell and gene therapies first, and available for common diseases, particularly those "for which there are no proven alternative treatments." Feb 2026, NEJM: one adequate and well-controlled study plus confirmatory evidence is the FDA's default basis for approval. Feb 2026 draft guidance: an externally controlled study against a well-characterized natural history can be the pivotal study. Confirmatory evidence includes mechanism, target engagement and "exposure-response on biomarkers and clinical outcomes." The product can target "a well-characterized downstream or compensatory mechanism with a clear mechanistic rationale." June 2026 draft guidance: six conditions under which an external control supports effectiveness. The plausible mechanism framework named as an example of FDA regulatory flexibility in critical settings. "Even small effects may be clinically meaningful when the effect is on survival or irreversible morbidity." Why it exists: to bring regulatory flexibility to individualized therapies where the conventional model does not fit. The guidance names gene and RNA therapies, then says "the general concepts may apply to other types of individualized therapies": therapies that target "a specific pathophysiologic abnormality serving as the root cause of a disease." The FDA's own announcement: the guidance "leaves open the potential that this framework may apply to additional tailored therapeutics provided they directly address the underlying specific cause of the disease." The framework is not a new approval standard. It is how the FDA reads evidence under the standard that already exists. That is exactly why it can be asked for today. 𝗪𝗵𝘆 𝗴𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗶𝘀 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗶𝘁 𝘄𝗮𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗳𝗼𝗿 No proven alternative: recurrent GBM has no established standard of care. Of 400+ trials since 2005, only one phase 3 in newly diagnosed and none in recurrent disease had shown a survival benefit. High and predictable mortality: the exact case FDA regulations name for historical controls, "certain malignancies." Life-threatening in the regulation's own terms: a disease "where the end point of clinical trial analysis is survival." Individualized: a different product for every patient, made from their own cells and their own tumor, aimed at the root cause, the broken instruction layer. Orphan designation in the US and Europe. 𝗧𝗵𝗲 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝘀𝘁𝘂𝗱𝘆 𝗶𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 331 patients, 94 sites, randomized, double blind. 64 of 99 placebo patients crossed over at recurrence, so survival was measured against 2,006 contemporaneous matched control patients from 15 randomized trials. Newly diagnosed: 19.3 vs 16.5 months, HR 0.80, p=.002. Alive at 5 years: 13.0% vs 5.7%. Recurrent: 13.2 vs 7.8 months, HR 0.58, p<.001. That is a 42% lower risk of death. The benefit widened over time, and it was largest in the patients who fare worst. Why no second trial? The completed trial, the crossover and the survival evidence make the case, and the FDA's June guidance names the ethical stake: after "a substantial decrease in mortality," a second trial "would generally present significant ethical concerns." 𝗧𝗵𝗲 𝟮𝟬𝟮𝟲 𝗿𝗲𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 The phase 3 paper named its own limitation: without patient-level control data, "propensity score matching could not be performed." The critics named the missing methods: "propensity score matching or inverse probability weighting." In 2026 Northwest obtained individual patient data from three independent randomized trials and had independent statisticians run exactly those two methods. Propensity score matching pairs each DCVax-L patient with control patients who had the same prognostic profile, so like is compared with like. Presented at BNOS in July 2026; peer-reviewed publication is the next step. Propensity score matching: HR 0.69 to 0.77. Median survival +3.4 to +6.3 months. p .004 to .027. The original cohort-level analysis showed +2.8. When the matching got finer, the benefit got bigger. The survival advantage held under both patient-level methods and was larger than the original cohort-level estimate. Northwest reports sensitivity analyses for hidden confounding; the published paper should give the values. The method has been tested in this exact disease. In May 2026, the INSIGhT investigators replaced their own randomized control arm with propensity-matched external controls. For three drugs that had failed randomized testing, the method also found no benefit: HR 1.00, 0.93, 0.88. "Carefully matched external controls" produced "treatment effect estimates that were similar" to the randomized analyses. The method did not invent a benefit. Applied to DCVax-L, it found one. And the authorship closes the loop. In 2023, Dana-Farber statisticians Rahman, Ventz and Trippa wrote that they were "not aware of independent validations of these analytic methods in a GBM trial context." Rahman and Trippa are the senior authors of the 2026 INSIGhT validation. The critics asked for patient-level data and a validated method. By 2026 both existed. That supports the method the DCVax-L reanalysis used; publishing that analysis in full is step one. And it is the form a BLA requires: FDA guidance says applications "must include" patient-level data for the external control arm. 𝗧𝗵𝗲 𝗙𝗗𝗔'𝘀 𝘀𝗶𝘅 𝘁𝗲𝘀𝘁𝘀 𝗳𝗼𝗿 𝗮𝗻 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 1. Well-defined natural history: 2,006 controls from 15 randomized trials. 2. Very similar populations: 14 prespecified criteria, chosen by an independent firm, validated against all 15 source trials, now matched patient by patient. 3. Similar treatments: in newly diagnosed disease, surgery, radiation and temozolomide in both groups. 4. Objective endpoint: death. 5. Comparable start: survival from randomization after radiotherapy in both groups. Drop the two control trials that admitted early progressors: HR still 0.80. 6. An effect too large to be bias: five-year survival more than doubled, HR 0.58 at recurrence, and the effect grew when matching tightened. 𝗧𝗵𝗲 𝗽𝗹𝗮𝘂𝘀𝗶𝗯𝗹𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮, 𝘄𝗼𝗿𝗱 𝗳𝗼𝗿 𝘄𝗼𝗿𝗱 The FDA's five elements, quoted exactly from its February 2026 draft guidance ( lines 26 to 32), each answered: 1. "Identifying a specific genetic, cellular, or molecular abnormality with a clear connection between specific alteration and disease indication." (line 26) ✓ Met: in GBM, the dendritic cells that should teach T cells what to attack are overridden by suppressive immune cells. A tumor never presented for attack grows unopposed. 2. "Developing a therapy that targets the underlying or proximate pathogenic biological alterations." (line 28) ✓ Met: DCVax-L supplies the patient's own dendritic cells, loaded with their own tumor and prepared outside the suppressive tumor environment, to restore tumor-directed T-cell instruction. 3. "Relying on a well-characterized natural history of the disease in an untreated population." (line 30) ✓ Met: 2,006 controls from 15 randomized trials, patient-level data from three more, no time-trend in survival 2012 to 2022. 4. "Confirming that the target was successfully drugged or edited or both." (line 31) ✓ Platform evidence documented; product-specific bridge required. After DC vaccination, cytotoxic T cells increased inside the tumor, and infiltration correlated with survival (P = 0.047); T cell infiltration in the UCLA vaccine-first arm. The FDA is open to confirmation "for a subset of patients"; the BLA should supply DCVax-L's own immune-monitoring results and the bridge to these studies. 5. "Demonstrating improvement in clinical outcomes or course." (line 32) ✓ Met: longer survival, five-year survival more than doubled, a bigger benefit under patient-level matching. The eight considerations attached, each answered: 1. An individualized therapy aimed at "a specific pathophysiologic abnormality" 2. A "compensatory mechanism with a clear mechanistic rationale" 3. Substantial evidence from "a single adequate and well-controlled clinical investigation with confirmatory evidence" 4. A natural history that lets the effect be "reasonably distinguished from natural variability" 5. An improvement not attributable to "alternative treatments or natural variability" 6. Prespecified analysis plans 7. A reason a new RCT is not feasible 8. A product that "can be manufactured to regulatory quality standards," made for every phase 3 patient: manufacturing experience documented, US CMC review required 13 of 13, every one in the FDA's own words, every one answered from the record, every open step named. 𝗧𝗵𝗲 𝗰𝗼𝗻𝗳𝗶𝗿𝗺𝗮𝘁𝗼𝗿𝘆 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, 𝗶𝗻 𝘁𝗵𝗲 𝗙𝗗𝗔'𝘀 𝗼𝘄𝗻 𝗰𝗮𝘁𝗲𝗴𝗼𝗿𝗶𝗲𝘀 Mechanism: in the DCVax-Direct phase 1 (a different product: activated dendritic cells injected into diverse solid tumors), more IL-8 and IL-12p40 from each patient's cells went with longer survival, p=0.023 and 0.024. Exposure-response, in the FDA's words. Related product: UCLA's 46-patient randomized phase 1 trial of its own tumor lysate DC vaccine, at EANO this Friday. Both arms got the vaccine; the order was randomized. Vaccine first, 555 days. Checkpoint first, 271. HR 0.32. The order matters: priming before checkpoint release more than doubled median survival. Across the class, a 2024 meta-analysis of seven dendritic cell vaccine trials, 3,619 patients, found HR 0.71 for survival, "indicating a true-positive result." Related indication: the FDA's own example is "a different stage of the same disease." DCVax-L worked at both stages. Independent natural history: national cancer registries, separate from the trial controls, as the guidance requires. Real-world data is expressly allowed. 𝗧𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗰𝗿𝗶𝘁𝗶𝗰𝗶𝘀𝗺𝘀, 𝗮𝗻𝘀𝘄𝗲𝗿𝗲𝗱 Three published critiques set out the case against the trial. Each point, answered from the record: Endpoint switched to survival? Progression could not be read: 256 of 494 scans needed adjudication. The critics agree: progression-free survival "is not an adequate endpoint for immunotherapy studies because of the phenomenon of pseudoprogression." Survival is the "gold standard," in their words. Cohort-level controls? The critics named the fix: propensity score matching or inverse probability weighting on patient-level data. That is exactly what 2026 did, and the benefit grew. Never validated in GBM? Two of the critics who raised it led the 2026 study showing patient-level external controls reproduce randomized results. Selection? Dropping the control trials that admitted early progressors changed nothing, as above. The benefit was larger in patients with more residual tumor, the opposite of what selection would produce. IDH, a tumor mutation linked to longer survival? Tested centrally in every DCVax-L patient. The gap is in the older control trials. Chosen after the fact? An independent firm, prespecified criteria, validation as above. Then a larger effect against different trials at the patient level. Company author? Data held by independent CROs, analyzed by independent statisticians. Run another trial? The completed program, crossover and survival evidence make a repeat unnecessary; the FDA's guidance names the ethical concern; the BLA documents why a new randomized design is not feasible or ethical. 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 The framework also requires that the product "can be manufactured to regulatory quality standards." DCVax-L was made for every patient in a 94-site phase 3, and in 2023 the UK regulator licensed the Sawston facility for commercial manufacturing, with products that "may be exported globally." A UK license is not US approval: FDA inspection and the potency assay go on the table at the pre-BLA meeting. 𝗕𝗲𝗻𝗲𝗳𝗶𝘁 𝗮𝗻𝗱 𝗿𝗶𝘀𝗸 Longer survival in a disease with no proven alternative at recurrence. 2,151 doses, 5 serious events even possibly related, no autoimmunity, no cytokine storm. It is the patient's own immune system, with one broken link rebuilt. A repair, judged the way a repair should be judged. 𝗧𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗶𝗹𝗲 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗿𝗲𝘃𝗶𝗲𝘄𝘀 Right to Try covers a product that has completed phase 1, is in active development and not on hold, and has an application on file. Filing the BLA satisfies the application condition; the others must still hold at that time. Patients must have a life-threatening disease, have exhausted approved treatments, be unable to join a trial and consent, and the manufacturer must choose to provide it. No separate FDA approval of each case. Build the program before filing. An expanded access treatment protocol (21 CFR 312.320) requires completed trials, active pursuit of approval and phase 3 evidence. The trials are complete and the phase 3 is published, so it does not have to wait for the BLA. Treatment can begin 30 days after the FDA receives the protocol, absent a hold. The usual reason a manufacturer holds back is risk: a serious event in a very sick patient gets blamed on the product. The FDA answered that in its April 2026 guidance: it "does not intend to deny, delay, or refuse to approve" a BLA "based solely on an adverse event occurring in the context of expanded access use," and "is not aware of any instances" where one prevented approval. Access is the bridge. Approval is the destination. This is not new for DCVax-L: it has been provided under Germany's hospital exemption and the UK Specials pathway. 𝗦𝗲𝗲𝗸 𝘁𝗿𝗮𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹, 𝘄𝗶𝘁𝗵 𝗮 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝘆 The framework's guidance: approval is traditional or accelerated "depending on the endpoints used." Survival is the endpoint, so the request is traditional, full approval, with no confirmatory-trial requirement. The FDA can still require postmarketing studies, and the framework's authors named the tool: "collecting real-world evidence to confirm continued preservation of efficacy." A registry of every treated patient, designed before approval. If accelerated approval becomes the route, the regenerative medicine advanced therapy (RMAT) statute lets post-approval requirements be met through registries and "postapproval monitoring of all patients treated with such therapy prior to approval." Every patient treated under Right to Try or expanded access counts. 𝗪𝗵𝗮𝘁 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝗻𝗲𝘅𝘁 Northwest has pursued the UK first. Its application there has been under review since late 2023, and in July 2026 the UK regulator confirmed it "remains under its initial regulatory review, has not been refused." The US filing is the step that remains. 1. Publish the patient-level reanalysis. 2. Lock in the patient-level control data rights the FDA requires. 3. Report the central IDH results and publish the phase 3 immune data. 4. Request RMAT designation now. FDA must answer within 60 days. 5. File the treatment protocol and build the Right to Try program. 6. Pre-BLA meeting with CBER: plausible mechanism review, six external-control tests answered, manufacturing and potency package. 7. File the BLA with priority review. 8. Build the registry. Approving DCVax-L this way would be the framework's proof beyond genetic disease: an individualized cell therapy, aimed at the root cause of the deadliest brain cancer, carried by a completed phase 3. A win for patients first. 𝗧𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗶𝘀 𝗱𝗼𝗻𝗲. 𝗧𝗵𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗶𝘀 𝘄𝗿𝗶𝘁𝘁𝗲𝗻. 𝗧𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗿𝗲 𝘄𝗮𝗶𝘁𝗶𝗻𝗴. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗹𝗲𝗳𝘁 𝗶𝘀 𝘁𝗼 𝗮𝘀𝘀𝗲𝗺𝗯𝗹𝗲 𝗶𝘁 𝗮𝗻𝗱 𝗳𝗶𝗹𝗲. Disclosure: long $NWBO. Commentary on published and presented data and public FDA documents. Not medical, legal, regulatory or investment advice. DCVax-L is investigational and not approved in the US. Regulatory strategy is the sponsor's decision.
Andrew Caravello, DO50,009 views • 21 days ago
$NWBO #DCVax #GBM Braelyn's mother said something tonight that deserves to be read twice: promising science means very little if the patients who need it cannot access it. I made this explainer because her story has a mechanism behind it, and that mechanism turns on one detail most people will read past. Her tumor tissue was properly preserved. That is not paperwork. A dendritic cell vaccine is built from the patient's own tumor, and it has to be whole tumor material, because the immune system's instruction step requires intact protein in order to work at all. A fragment cannot do it. A prediction cannot do it. The tissue is the curriculum, and it exists for a few hours in an operating room and then it is gone forever. Braelyn nearly lost that window. Not because the science was unavailable, but because nobody told her family it mattered before she went under. Dr. Liau operated, removed roughly 90% of a tumor spanning three lobes, and the tissue was preserved and sent to England. She has had three induction doses and a booster. Tonight the UCLA tumor board found no visible tumor, including the portion that had to be left behind. Her radiation, her surgery, her vaccine and her Keytruda are all in that result, and I'm not going to pretend I can separate them. What I can say is that three of those four options were available to her the whole time, and the fourth almost wasn't, for a reason that had nothing to do with biology. Every glioblastoma patient going to the OR this week faces the same window. Most of them will never be told it exists. That is a fixable problem. It should already have been fixed. No evidence of disease. Congratulations, Braelyn. 🙏🏻 #DCVaxForBraelyn
Andrew Caravello, DO30,244 views • 29 days ago
$NWBO #𝗗𝗖𝗩𝗮𝘅-𝗟: 𝗧𝗵𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗶𝗻 𝗣𝗹𝗮𝗶𝗻 𝗧𝗲𝗿𝗺𝘀 A short, plain-language reading of the survival evidence for DCVax-L in #glioblastoma, and what it means under the MHRAgovuk guideline on external control arms. 📊 𝗣𝗔𝗥𝗧 𝗢𝗡𝗘: 𝗪𝗛𝗔𝗧 𝗧𝗛𝗘 𝗧𝗥𝗜𝗔𝗟 𝗙𝗢𝗨𝗡𝗗, 𝗔𝗡𝗗 𝗪𝗛𝗬 𝗜𝗧 𝗠𝗔𝗧𝗧𝗘𝗥𝗦 DCVax-L more than doubled five-year survival, and the benefit is durability: a subset gets lasting disease control and simply stays alive. 💉 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴 𝗶𝘀 DCVax-L is a personalized cancer vaccine for glioblastoma, the deadliest form of brain cancer and a designated orphan disease. It is a living drug: its active ingredient is the patient's own immune cells, primed with proteins from that patient's surgically removed tumor, so the immune system learns to attack the cancer. Unlike a chemical drug that is metabolized and cleared, it switches on a living immune response that keeps working long after the injection. Glioblastoma comes back in almost everyone: even with the full standard of surgery, radiation, and temozolomide chemotherapy, most patients live under two years, and only about one in twenty reaches five. DCVax-L is given on top of that standard care, not in place of it: every patient in the trial received surgery, radiation, and temozolomide, and the vaccine was added to it, so the comparison measures what the vaccine adds. For two decades, nearly every new drug tried in this disease has failed. That is the backdrop against which any positive result must be judged. 📈 𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗳𝗼𝘂𝗻𝗱 In a Phase 3 trial of 331 patients, those who received DCVax-L lived longer. At the median the gain looks modest, about three months (19.3 versus 16.5). The number that matters sits at the far end of the survival curve: more than twice as many vaccine patients were alive at five years, 13.0% versus 5.7%, and a few reached ten years in a disease that usually kills within three. In patients whose tumor had already returned, the effect was larger still, cutting the risk of death by about 42%. 👥 𝗘𝘃𝗲𝗿𝘆 𝗴𝗿𝗼𝘂𝗽 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝗲𝗱, 𝗲𝘃𝗲𝗻 𝘁𝗵𝗲 𝗵𝗮𝗿𝗱𝗲𝘀𝘁 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 The benefit was not confined to the easy cases. Of the six prespecified subgroups the trial examined, every single one favored DCVax-L, and there was no group in which it did worse than standard care. The largest gains came in patients whose tumors carry MGMT methylation, who reached a median survival of 30.2 months from randomization against 21.3 for the controls. But even the hardest-to-treat patients, whose tumors lack that methylation, resist standard chemotherapy, and carry the worst prognosis in this disease, still came out ahead with the vaccine, at a hazard ratio of 0.93. A treatment that helps across the whole population, and helps most where the biology is most favorable, is acting like a real drug. 📉 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗺𝗲𝗱𝗶𝗮𝗻 𝗵𝗶𝗱𝗲𝘀 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹 𝘀𝘁𝗼𝗿𝘆 That five-year number is the whole story, and the median buries it. Almost every treatment that ever helped in glioblastoma did the same modest thing: it slid the survival curve a few months to the right, then let it fall back. Doubling five-year survival is different in kind. A three-month gain at the median cannot, by itself, double the fraction alive at five years. The only shape that produces both numbers is a split: most patients get the small delay the median measures, while a subset gets durable disease control that lasts for years, well past where glioblastoma should have ended them. That subset is the long tail of the curve, and it is where the benefit lives. A median ignores extremes, the way a town's median income tells you nothing about its millionaires. The real story is not a longer delay; it is that a meaningful share of patients simply stay alive. 🧬 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗽𝗿𝗲𝗱𝗶𝗰𝘁𝘀 𝘁𝗵𝗶𝘀 𝘀𝗵𝗮𝗽𝗲 The tail is not luck. It is what this biology is built to produce. The vaccine carries proteins from the patient's own tumor, so it aims the immune system at whatever that tumor is made of, not a fixed short list of targets. And it amplifies: one trained immune cell drives many others that multiply into cancer-killers. Andres Salazar, the neurologist who developed poly-ICLC into the clinical adjuvant given with the vaccine, puts it in a line: you start the fire, and you keep it burning. A response like that does not produce a one-time bump. It builds and widens over time. What matters is not just that a response forms, but what kind. Dendritic cells are the immune system's master switch for that, the cells that set what kind of attack the body mounts, and this vaccine is built from them. It drives what immunologists call a type 1 polarized response: an interferon-driven, cytotoxic program aimed squarely at the tumor. That direction comes from the vaccine itself; the poly-ICLC adjuvant given with it drives the same interferon program and sustains it. That is the active ingredient, and it has been measured. In UCLA studies of this approach, the patients whose immune systems mounted the strongest interferon response lived the longest. The response also spreads. In a different cancer, a vaccine carried on this same poly-ICLC adjuvant drove more than 70% of a patient's cancer-killing T cells to target proteins that were never in the vaccine: the immune system outgrew its original targets and went after the rest of the tumor on its own. This is called epitope spreading, and it is not particular to one tumor; it is what this kind of response does, and it is the kind of response DCVax-L builds. That breadth is the likeliest thing separating the long-term survivors from everyone else, a response that breaks past its targets and clears the disease rather than one that stays caged and stops. There is even a tell in who benefits most: the effect is largest in tumors whose biology builds up more mutations under chemotherapy, and more mutations mean more targets for a whole-tumor vaccine to find. The same logic explains what the vaccine is not, and what it does not need. Checkpoint inhibitors, the drugs that release the immune system's brakes, have failed on their own in glioblastoma because there was no active response to release; the vaccine supplies that response first. That makes the vaccine the natural foundation for combination therapy. Combining it with its poly-ICLC adjuvant, made by Oncovir, has already shown meaningful survival gains in a published analysis. In the pivotal trial, the vaccine's proven benefit came added on top of standard chemotherapy and radiation; the newer question is how much the immune response can carry on its own. A UCLA trial is now testing that in patients whose tumors have returned, adding #Keytruda (pembrolizumab), the checkpoint antibody from $MRK, in a regimen built entirely around the immune response with no chemotherapy or radiation in it at all. Its interim survival curve shows the shape the biology predicts. In the arm given the vaccine and Keytruda together after surgery, the curve does not fall away but flattens into a plateau, with roughly 65% of patients still alive well past the point where recurrent glioblastoma kills nearly everyone. That plateau is the signature of a response that took hold and lasted, the type 1 attack forming durable immune memory so that once the disease is controlled it stays controlled. That is where this points, and where it is already arriving, a treatment that works through the response itself, one that could in time lean less on the harsh radiation and chemotherapy that have defined glioblastoma care and barely moved its survival. These are interim results, from Prins, Cloughesy, and Liau at UCLA. 🔍 𝗣𝗔𝗥𝗧 𝗧𝗪𝗢: 𝗜𝗦 𝗜𝗧 𝗥𝗘𝗔𝗟? The trial was randomized, an independent experiment shows the outside comparison is trustworthy, and every separate check points the same way. 🤔 𝗧𝗵𝗲 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝘄𝗵𝘆 𝗶𝘁 𝗺𝗶𝘀𝘀𝗲𝘀 𝘁𝗵𝗲 𝗺𝗮𝗿𝗸 So much for what happened; the harder question is whether to believe it. The trial has the feature critics attacked: it could not keep a normal placebo group, because patients assigned to placebo were allowed, by design and by medical ethics, to switch to the vaccine once their cancer returned, and almost all did. That erased the internal comparison, so survival was measured against closely matched patients from other completed trials, an approach called an external control, which critics argued could tilt toward the vaccine. What the objection misses is where the randomization went. This was a randomized, blinded trial. The patients who got the vaccine were assigned to it at random, not hand-picked, so the treated group is an ordinary slice of the trial population, not a favorable one. The crossover removed the placebo group but never touched how patients were assigned. That leaves exactly one place for bias to enter, the outside comparison group, which is precisely what the next checks test. ✅ 𝗧𝗵𝗲 𝗰𝗵𝗲𝗰𝗸 𝘁𝗵𝗮𝘁 𝗺𝗮𝗸𝗲𝘀 𝗶𝘁 𝘁𝗿𝘂𝘀𝘁𝘄𝗼𝗿𝘁𝗵𝘆 Before trusting a scale to weigh something unknown, you confirm it reads zero with nothing on it. That is what the calibration does, and it is the strongest part of the case. A separate, independent randomized trial called INSIGhT was run through the very same external-control method, and it gave two answers. First, three experimental drugs that had already failed were run through it, and it correctly found nothing (hazard ratios of 1.00, 0.93, and 0.88): the method does not manufacture a benefit where none exists. Second, INSIGhT's external controls were set head to head against its own randomized internal controls, and they were statistically indistinguishable. In this disease, an external control reproduces the answer a real randomized control would have given, and because that trial belonged to a different group, no one can say a sponsor graded its own work. The one place bias could enter, the control side, is the one place an independent randomized experiment certified as clean. There is a deeper fit worth naming, and it is what makes the two halves of this case one. The same instrument that reported those three failures as failures reads the vaccine as a success, and the biology says why: those drugs could not hold a tumor this varied, and the vaccine builds the broad, lasting response that finally does. One method, opposite readings, and one mechanism behind both. The statistics and the biology are not two arguments. They are the same argument seen twice. 🃏 𝗪𝗮𝘀 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻 𝘀𝘁𝗮𝗰𝗸𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘃𝗮𝗰𝗰𝗶𝗻𝗲'𝘀 𝗳𝗮𝘃𝗼𝗿? A natural worry is that the outside comparison was arranged after the fact to flatter the vaccine. The trial was built to prevent that. The patients to compare against, and the rules for matching them, were fixed in writing before anyone saw results, and an independent firm, not the company, chose the comparison trials against those rules. The trial also switched its main measure partway through, from delaying tumor growth to overall survival, but that was not a maneuver: immune treatments cause a harmless swelling that mimics tumor growth on scans and made the growth measure unreliable, and the switch was made while everyone was still blinded. Three further checks point the same way. Survival in this disease has not improved over the years the comparison spans, so same-era controls are sound. When the borrowed controls were tested directly, the comparison came out conservative rather than flattering. And the controls were counted from the same point in the disease as the vaccine patients, so neither side got a head start. Where the comparison can err, it errs against the drug. 🔬 𝗧𝗵𝗲 𝗺𝗼𝗿𝗲 𝗰𝗮𝗿𝗲𝗳𝘂𝗹 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗺𝗮𝗱𝗲 𝘁𝗵𝗲 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗯𝗶𝗴𝗴𝗲𝗿, 𝗻𝗼𝘁 𝘀𝗺𝗮𝗹𝗹𝗲𝗿 The first comparison used whole groups. A sharper one became possible once patient-level records from three other trials could be obtained, pairing each vaccine patient with controls matched on the traits that drive survival in glioblastoma, above all MGMT methylation status, matched exactly, plus age, sex, extent of surgery, residual disease, and performance status. When the comparison got sharper, the benefit grew in every one of these analyses. The original cohort-level estimate was 2.8 months. Patient-level matching across the three trials put the gain between 3.4 and 6.3 months, and a method that weights patients rather than pairing them put it between 3.4 and 4.3, with several of the matched comparisons roughly doubling the original figure. The hazard ratio moved the same way, from 0.80 to between 0.69 and 0.77. The direction matters. A real effect blurred by crude matching gets clearer when the matching improves, while a biased one tends to shrink. It got stronger. 🕵️ 𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗵𝗶𝗱𝗱𝗲𝗻 𝗯𝗶𝗮𝘀 𝘄𝗼𝘂𝗹𝗱 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗲𝘅𝗽𝗹𝗮𝗶𝗻 𝘁𝗵𝗶𝘀 𝗮𝘄𝗮𝘆 A fair question is how much hidden bias it would take to erase the result. Statisticians measure that with the E-value, and here a hidden factor would have to be about as strong as age is on survival, would also have to drive who received the vaccine, and would have to have escaped the decades of research that mapped every known risk factor in this disease. A second, independent check, Rosenbaum's Gamma, comes at it from the other side, asking how large an unseen imbalance between matched patients it would take to break the result, and it reaches the same verdict. Every factor strong enough to matter was already matched. A hidden one that clears that bar is not plausible. 🔒 𝗪𝗵𝘆 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁 𝗶𝘀 𝗵𝗮𝗿𝗱 𝘁𝗼 𝗳𝗮𝗸𝗲 The strongest point is not any single result. It is that a hidden bias big enough to explain the effect away would have to produce the same answer in every independent test at once: • The independent randomized calibration trial. • Three separate comparison trials, drawn from different studies. • Two different statistical methods that handle the data in different ways. • A separate pooled analysis of other dendritic-cell vaccine trials. • The internal math of the survival curve, which points to the same result (about 0.71 at five years) that the patient matching found. And it would have to fall in the exact direction the biology predicted before any data existed: a slow, widening benefit concentrated in long-term survivors. A single hidden factor that could forge all of that at once is not a hidden factor. It is a coincidence that does not happen. 🩺 𝗣𝗔𝗥𝗧 𝗧𝗛𝗥𝗘𝗘: 𝗪𝗛𝗔𝗧 𝗜𝗧 𝗠𝗘𝗔𝗡𝗦 The drug is nearly free of harm, the evidence fits an established and approved regulatory path, and what remains unrun changes nothing about the case. 🛡️ 𝗧𝗵𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 Two things decide whether a real effect reaches patients: whether the drug is safe enough to use, and whether regulators will accept the evidence. The first is settled. Across 2,151 doses, only five serious side effects were even possibly related to the vaccine, with no autoimmunity and no cytokine storm. It is made once, in about eight days, then stored and given as a simple injection. When a treatment barely harms, the benefit needed to justify it falls, and the benefit here clears that lower bar easily. ⏳ 𝗪𝗵𝘆 𝘁𝗵𝗲 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗱𝗮𝘁𝗮 𝗮𝗽𝗽𝗲𝗮𝗿𝗲𝗱 𝗼𝗻𝗹𝘆 𝗻𝗼𝘄 A reasonable person asks why the sharper analysis appeared in 2026 and not in 2023. The answer is access, not choice. The patient-level analysis was written into the trial's plan from the start, to run if and when the data could be obtained. The company tried and could not get it in 2023, because the trials that held it had not released it; it became available later through a data-sharing repository, on the data owners' timeline, not the company's. The stronger analysis was always the plan. It was waiting on data that other parties control. 🔄 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗵𝗼𝘀𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘁𝘂𝗿𝗻𝗲𝗱 𝗮𝗹𝘀𝗼 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝗲𝗱 The vaccine helped not only newly diagnosed patients but also those whose tumor had already come back, and there the effect was the largest seen anywhere in the trial. In that group, median survival ran 13.2 months from recurrence against 7.8 for the controls. The separation opened immediately, with 90.6% of vaccine patients alive at six months against 64.0% of controls, and the lead held to the later marks, where survival more than doubled: 20.7% against 9.6% at two years, 11.1% against 5.1% at two and a half. These are the original cohort-level results, already published. The high-resolution patient-level matching that was applied to the newly diagnosed group has not yet been done here, for a practical reason: it needs patient records from other recurrent-cancer trials, held by a European research organization that shares them through its own formal request. Obtaining them is a routine next step, not an obstacle, and the newly diagnosed experience suggests the sharper analysis would only make the recurrent result stronger. The approval case rests on the newly diagnosed evidence, so nothing important depends on this step; it would simply sharpen a result that is already the strongest in the trial. 🏛️ 𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 Regulators do not treat an external control as a first choice, but the MHRA's guideline allows it in exactly this situation: a severe disease where a placebo trial is not ethical or feasible, and an effect large enough to interpret despite the design. The guideline even gives its own worked example of an acceptable external control, and it reads almost like a description of this trial: a rare disease, no ethical placebo, same-era standard-of-care controls, an objective survival endpoint, and an effect too large to blame on bias. DCVax-L fits on every count, and it was the first medicine ever to receive the MHRA's Promising Innovative Medicine designation, which asks essentially the same questions. The newly diagnosed case carries the decision on its own evidence, and regulators weigh that evidence against the disease it treats: in a cancer this lethal, with nothing better on offer, the question is whether the benefit is large, clear, and consistent enough to act on, and a benefit of this size, pointing the same way from every direction, is. 📜 𝗧𝗵𝗶𝘀 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗱𝗼𝗻𝗲 𝗯𝗲𝗳𝗼𝗿𝗲, 𝗮𝗻𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 External controls are not a novelty invented for this drug. Over the past two decades they have factored into roughly forty-five drug approvals by the United States regulator, each granted under the conditions that apply here: a serious or rare disease, a placebo that would be unethical, and high unmet need. Regulators do not grant this lightly. They grant it when the disease is serious, its course is predictable and objectively measured, and the effect is large. Glioblastoma meets all three. The named cases cover every part of this disease's profile. Defibrotide, for a life-threatening transplant complication, was approved on a propensity-score comparison to a historical control, the same kind of method used here. Blinatumomab, for an aggressive relapsed leukemia, is the precedent for a fast-killing cancer, cleared by both the United States and European regulators. Cerliponase alfa is the precedent for a fatal brain disease, cleared by both agencies on treated patients versus a matched natural-history group. Glioblastoma is both at once, a fast-killing cancer of the brain, read by the same method, so no part of its profile lacks a close approved precedent. And on the one axis that governs how far an external-control result can be trusted, DCVax-L goes beyond all three. Each of those drugs was tested in a single-arm trial, with no randomization at all. DCVax-L began as a randomized trial and became an external-control comparison only when ethics consumed its placebo group. It sits in that tradition, and at the top of it. 🎯 𝗧𝗵𝗲 𝗯𝗼𝘁𝘁𝗼𝗺 𝗹𝗶𝗻𝗲 This began as a randomized trial. Medical ethics forced it into an external-control comparison. Every independent way of checking it, on different data and different math, points the same direction, and the biology predicted that direction in advance. The first analysis did not overstate the vaccine's effect. Read with the right tools, it understated it.
Andrew Caravello, DO11,406 views • 3 months ago
🧬 The Recipe: How One Ovarian Cancer Trial Rebuilds the Immune System the Disease Switched Off A node-by-node case for durable immunity in the cancer that has resisted checkpoint blockade $NWBO and its #DCVax dendritic-cell platform sit at the heart of a new front-line #OvarianCancer trial, the same instructor-cell technology now aimed at the cancer that checkpoint blockade has barely touched. Advanced ovarian cancer kills more women than any other gynecologic malignancy, and it has shrugged off the #immunotherapy revolution almost entirely. Checkpoint blockade on its own reaches an objective response rate near eight percent in this disease, the figure from the $MRK #KEYNOTE-100 trial. The tumors are cold, the mutational burden is low, and the peritoneal cavity is a suppressive field that shuts an immune attack down before it can start. Two decades of single-agent vaccines and single-agent checkpoint drugs have not changed the survival math. Most patients respond to first-line chemotherapy and then relapse, and once the disease returns, the odds turn hard against them. For the patient living that diagnosis, a durable response is the only outcome that counts, and that is the one thing the field has not delivered. A Phase 2 trial opening at #UPMC Hillman in the second half of 2026, #NCT07634094, takes a different route. It does not add one more drug to the pile and hope. It treats ovarian cancer as one clinical face of a single, definable failure, and it rebuilds the broken machinery one node at a time. The sponsors are Pawel Kalinski MD PhD, $NWBO and $AIM. Here is the full logic, and why it is built to produce a response that lasts. 🔒 The hidden lesion: a silencing cascade Ovarian tumors run a self-reinforcing program that switches off the immune system's command center. It starts with chronic inflammation. Senescence-associated secretions and prostaglandin E2, the product of the COX-2 enzyme, keep the signaling protein STAT3 locked on. Persistent STAT3 pulls the silencing enzymes DNMT1 and EZH2 onto a single master gene, IRF8. That gene is the identity switch for the type 1 conventional dendritic cell, the cDC1, the one cell that licenses killer T cells with bioactive Silence IRF8 and the instructor disappears. With it gone, the tumor secretes decoy chemokines that recruit regulatory T cells, killer cells never receive their orders, and the disease grows in immunological darkness. This is not a quirk of ovarian cancer. The same cascade shows up in chronic infection and in aging tissue. Ovarian cancer is one face of a convergent mechanism, which is why a fix that works here points well beyond it. 🔄 The recipe: the cascade run in reverse Every component of the regimen corrects one node of that cascade. Pull out any single arm and the suppression reasserts itself through the others. That is what separates this from a kitchen sink: each part is load-bearing. · Celecoxib lifts the upstream PGE2 brake that keeps the silencing signal switched on. · Autologous, tumor-loaded alpha-DC1 supplies the instructor function from outside the silencing field, loaded with the whole tumor. This is the rebuilt command center the disease erased. · #rintatolimod, the selective TLR3 agonist marketed as #Ampligen, plus interferon-alpha flips the chemokine code tumor-selectively, from the CCL22 that recruits regulatory cells to the CXCL10 and CCL5 that pull in killers. #Bioferon · The alpha-DC1 program imprints CXCR3 and CCR5 homing receptors on the instructed CD8 cells, so they reach the tumor instead of circulating uselessly. · Cisplatin raises stress ligands so the killers can destroy low-antigen escape variants through the DNAM-1 and NKG2D receptors, closing the door on the engine of recurrence. · Paclitaxel plus the interferons repolarize suppressive M2 macrophages back to the supportive M1 state. · $MRK #Keytruda, releases the PD-1 brake last, only after the tumor has been made hot. The order is not cosmetic. The checkpoint comes last for a reason that most combination trials get wrong. 🔗 Why the combination is required, not additive Checkpoint blockade does not activate killer T cells by itself. Published work shows that anti-PD-1 efficacy depends on dendritic cells producing IL-12 inside the tumor (Garris, Immunity 2018). If the instructor is silenced and no IL-12 is being made, pembrolizumab has nothing to set loose. It is releasing a brake on a car with no engine. So restoring the IL-12 signal is the precondition for the checkpoint to do anything in this disease, not an optional add-on to it. The alpha-DC1 vaccine rebuilds the engine. Pembrolizumab takes the brake off. Neither delivers without the other. The relationship is causal, and that is the single idea the whole regimen is organized around. ⏳ Why the response should last A response that fades is not a cure, and durability is engineered here on four fronts at once. · Breadth. The vaccine is loaded with the whole tumor, not a single antigen, so the immune system learns the entire target and the tumor cannot escape by dropping one marker. · A lowered killing threshold. The DNAM-1 and NKG2D signals let killers finish variants that have shed antigen, while the requirement for true tumor recognition is preserved, so normal tissue is passed over. · Memory programming. Bioactive IL-12p70 does what ordinary dendritic-cell expansion cannot. It programs a self-renewing, TCF1-positive stem-like CD8 reservoir, the very population that predicts lasting benefit from checkpoint blockade (Goswami, Clinical Cancer Research 2025). · A self-reinforcing organ. Restored type 1 signaling matures tertiary lymphoid structures inside the tumor, the local factories from which durable immunity is rebuilt long after the last dose. 📊 Already partly de-risked This is not a first guess. The chemokine-and-checkpoint backbone was already tested in recurrent platinum-sensitive ovarian cancer in trial NCT03734692: intraperitoneal cisplatin plus rintatolimod plus pembrolizumab. That study produced an objective response rate near fifty percent, several times the roughly eight percent checkpoint blockade reaches alone in $MRK #KEYNOTE-100, accompanied by the exact chemokine shift the model predicts, the rise in CXCL9, CXCL10, and CXCL11 that a restored type 1 program produces. $MRK collaborated on it and supported it, and the final primary endpoint reported in May 2026. #SITC26 #ASCO26 The new trial adds the missing piece, the alpha-DC1 instructor whose intellectual property traces to #RoswellPark, and moves the whole regimen to the front line, where the tumor is largest and the antigen supply is richest. It is the same spine, established in recurrent disease, now armed with the one component that was absent. 🔬 A trial built to be read, not just won NCT07634094 enrolls twenty-eight patients with Stage III to IV epithelial ovarian, tubal, or peritoneal cancer, chemo-naive, in the neoadjuvant #neoadjuvant setting. #OvarianCancerAwareness #gyncsm #BRCA Treating before surgery buys the cleanest possible readout: the resected tumor itself. The co-primary endpoints are the safety of the full combination and pathologic complete response at debulking. A pathologic complete response, meaning no viable tumor left in the surgical specimen, is one of the most demanding endpoints in solid-tumor #oncology and a recognized marker of long-term benefit. The design also reads the mechanism directly. It looks for the chemokine switch, the rise in intratumoral CD8 cells with a favorable ratio to regulatory cells and a TCF1-positive phenotype, the falling inflammatory tone, and the specific signature of restored pulsed IL-12p70 against preserved bulk IL-12. The study is built to show whether the mechanism engaged, not only whether tumors shrank. Enrollment is expected to begin in the second half of 2026, and because the central readout is the surgical specimen rather than years of follow-up, the first mechanistic signals should arrive relatively early. 🏭 Why this is a platform, not a one-off The instructor cell at the center of this regimen is the same dendritic-cell platform Northwest Biotherapeutics has built its company around. #DCVax extended survival in Phase 3 glioblastoma (JAMA Oncology, 2023), and a UK marketing application is pending with MHRAgovuk. The same approach has already worked in ovarian cancer. At the University of Pennsylvania, a personalized whole-tumor dendritic-cell vaccine in recurrent ovarian cancer was well tolerated and induced broad antitumor T-cell responses that tracked with significantly longer survival, with two-year survival of one hundred percent in the immune responders against twenty-five percent in non-responders (Tanyi et al., Science Translational Medicine, 2018). Those dendritic cells were loaded with the patient's own whole tumor and activated toward the same type 1 program this regimen rebuilds. That is the proof of principle, and this trial is the more complete version of it. The dendritic cell here is engineered for higher, sustained IL-12p70. It is given in the front line, where the antigen supply is richest, rather than in heavily pretreated relapse. The suppressive microenvironment is reprogrammed in parallel rather than left intact, and the checkpoint is released at the end. The Penn vaccine carried the immune response largely on its own. This regimen clears the field for it first, then takes the brake off. The historical knock on personalized cell therapy was manufacturing: bespoke, hand-built, hard to scale. Northwest Biotherapeutics has been answering that directly. #Flaskworks #EDEN, the closed, automated manufacturing system the company acquired, standardizes production and removes the single-site hand manufacturing that limited earlier programs. The Sawston facility #Sawston in the UK, operated by #AdventBioServices, a wholly owned Northwest Biotherapeutics subsidiary, under MHRA good-manufacturing standards, is bringing its first Grade C suite online in 2026, a step anticipated to more than double capacity, with a dedicated leukapheresis clinic already running. The company has also added senior leadership to drive the platform, naming the biopharmaceutical veteran Dr. Annalisa Jenkins as a strategic adviser. The consequence is concrete. If the mechanism reads out in the resected tumor, the system that delivers it is already being built to scale, across the many solid tumors that run the same silencing cascade. One trial, read correctly, does not validate a single drug. It tests a repeatable way of rebuilding antitumor immunity. That reach is the point. The same instructor sits at the center of the silencing cascade across most solid tumors, which is why the dendritic-cell platform is framed around the approach itself rather than a single indication. A front-line ovarian readout that confirms the mechanism would be evidence for the method, not for one tumor type alone. The needle moves on the tissue, not on the thesis, and no paragraph substitutes for the pathology report. What the design offers is a complete, testable mechanism for durable immunity in ovarian cancer, paired with a manufacturing system already capable of producing it at scale. The readout in the resected tumor will speak for itself. Not financial advice. Do your own research. #DCVaxForBraelyn
Andrew Caravello, DO10,459 views • 4 months ago
No more content to load